Quinolines (including Hydrogenated) Patents (Class 514/253.06)
  • Patent number: 6479495
    Abstract: Novel aminoalkylphenols, intermediates and processes for the preparation thereof, and methods of relieving memory dysfunction utilizing the aminoalkylphenols or compositions thereof are disclosed.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: November 12, 2002
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Raymond W. Kosley, Jr., Mark G. Palermo, Stephen J. Shimshock, Veronica Wolf
  • Patent number: 6469006
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with indoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Grant
    Filed: May 16, 2000
    Date of Patent: October 22, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wade S. Blair, Milind Deshpande, Haiquan Fang, Pin-Fang Lin, Timothy P. Spicer, Owen B. Wallace, Hui Wang, Tao Wang, Zhongxing Zhang, Kap-Sun Yeung
  • Publication number: 20020147192
    Abstract: Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.
    Type: Application
    Filed: September 17, 2001
    Publication date: October 10, 2002
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
  • Publication number: 20020143019
    Abstract: A compound of formula (IA) or the pharmaceutically acceptable acid addition salts thereof wherein: R1, R2, R3, R4 and R5 are the same or different and represent hydrogen, halogen, C1-C6alkyl, C1-C4-alkoxy, C1-C4akylthio, hydroxy, 1 amino, mono(C1-C6) alkylamino, di(C1-C6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy; R6 is hydrogen or C1-C6alkyl; W is nitrogen, COH, or CH; Y and Z independently represent nitrogen or CH; and A represents an alkylene group of from 2-5 carbon atoms optionally substituted with one or more alkyl groups having from one to four carbon atoms. The compounds of the invention demonstrate high affinity and selectivity in binding to the D4 receptor subtype.
    Type: Application
    Filed: October 23, 2001
    Publication date: October 3, 2002
    Applicant: Neurogen Corporation
    Inventor: Xiao-shu He
  • Publication number: 20020132806
    Abstract: This invention relates to compounds of Formula I 1
    Type: Application
    Filed: January 22, 2002
    Publication date: September 19, 2002
    Inventors: Roger Ruggeri, Douglas Wilson
  • Publication number: 20020128269
    Abstract: Substituted heterocyclic compounds for treating multidrug resistance are disclosed. Compositions and methods of use for the substituted heterocyclic compounds are disclosed.
    Type: Application
    Filed: December 19, 2000
    Publication date: September 12, 2002
    Inventors: Charles Raymond Degenhardt, David Joseph Eickhoff
  • Publication number: 20020128271
    Abstract: This invention provides a compound of the formula (I): 1
    Type: Application
    Filed: December 5, 2001
    Publication date: September 12, 2002
    Applicant: Pfizer Inc.
    Inventors: Yasuhiro Katsu, Makoto Kawai, Hiroki Koike, Seiji Nukui
  • Patent number: 6448244
    Abstract: The present invention concerns novel water-soluble azole compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof; as antifungals; their processes for preparation, composition containing them and their use as a medicine.
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: September 10, 2002
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Lieven Meerpoel, Leo Jacobus Jozef Backx, Louis Jozef Elisabeth Van der Veken
  • Publication number: 20020123498
    Abstract: Substituted heterocyclic compounds for treating multidrug resistance are disclosed. Compositions and methods of use for the substituted heterocyclic compounds are disclosed.
    Type: Application
    Filed: December 19, 2000
    Publication date: September 5, 2002
    Inventors: Charles Raymond Degenhardt, David Joseph Eickhoff
  • Publication number: 20020119979
    Abstract: Substituted acyclic compounds are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent.
    Type: Application
    Filed: December 19, 2000
    Publication date: August 29, 2002
    Inventors: Charles Raymond Degenhardt, David Joseph Eickhoff
  • Patent number: 6423751
    Abstract: A use for agents that disrupt actin cytoskeletal organization is provided. In the instant invention, agents that disrupt actin cytoskeletal organization are found to upregulate endothelial cell Nitric Oxide Synthase activity. As a result, agents that disrupt actin cytoskeletal organization are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.
    Type: Grant
    Filed: July 14, 1998
    Date of Patent: July 23, 2002
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: James K. Liao
  • Patent number: 6423717
    Abstract: Novel sulphonamide derivatives having CNS activity, processes for their preparation and their use as medicaments are disclosed.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: July 23, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Steven Mark Bromidge, Francis David King, Paul Adrian Wyman
  • Publication number: 20020082262
    Abstract: Substituted bicyclic compounds for treating multidrug resistance are disclosed. Compositions and methods of use for the substituted bicyclic compounds are disclosed.
    Type: Application
    Filed: December 19, 2000
    Publication date: June 27, 2002
    Inventors: Charles Raymond Degenhardt, David Joseph Eickhoff
  • Patent number: 6410563
    Abstract: Novel substituted 8-arylquinolines, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, are PDE4 inhibitors.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: June 25, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Denis Deschenes, Daniel Dube, Michel Gallant, Yves Girard, Patrick Lacombe, Dwight MacDonald, Anthony Mastracchio, Helene Perrier
  • Publication number: 20020072520
    Abstract: Sulfonylcarboxamide derivatives of formula I, their physiologically acceptable salts and/or physiologically functional derivatives, methods of making these compounds, their use for preparing medicines for the prevention and treatment of hyperlipidemia and arteriosclerotic disorders.
    Type: Application
    Filed: September 27, 2001
    Publication date: June 13, 2002
    Inventors: Reinhard Kirsch, Hans-Ludwig Schaefer, Eugen Falk, Horst Hemmerle
  • Patent number: 6399614
    Abstract: The present invention is directed to novel 1-(N-phenylaminoalkyl)piperazine derivatives substituted at the position 2 of the phenyl ring. Pharmaceutical compositions comprising the compounds of the invention also are contemplated. The compounds of the present invention also are contemplated for use in treating neuromuscular dysfunction of the lower urinary tract in a mammal.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: June 4, 2002
    Assignee: Recordati S.A. Chemical and Pharmaceutical Company
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
  • Use
    Patent number: 6399617
    Abstract: The invention provides a method of treatment or prophylaxis of obesity, comprising administering to a patient in need of such treatment a therapeutically effective amount of an aryl sulfonamide compound of formula (I) or formula (II) wherein the substituents are as described in the specification.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: June 4, 2002
    Assignee: Biovitrum AB
    Inventors: Patrizia Caldirola, Sukhwinder Jossan, Kjell S. Sakariassen, Jan Svartengren
  • Patent number: 6387389
    Abstract: The present invention provides sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines, pharmaceutical compositions comprising the same, and a method of using such sustained-release derivatives to bind the dopamine transporter to achieve a desired effect, such as antagonism of dopamine reuptake inhibitors, such as cocaine, or dopamine releasers or norepinephrine and/or serotonin reuptake inhibitors, such as methamphetamine.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: May 14, 2002
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Richard B. Rothman, Kenner C. Rice, David Lewis, Dorota Matecka, John R. Glowa
  • Publication number: 20020049219
    Abstract: The present invention relates to a process for preparing 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen-2-ol compounds useful as an estrogen agonist.
    Type: Application
    Filed: May 7, 2001
    Publication date: April 25, 2002
    Inventor: Kevin K. Liu
  • Patent number: 6376494
    Abstract: This invention relates to compounds which have activity as 5-HT1A agonists and antagonists which may be useful for the treatment of anxiety, depression, cognitive deficits, and prostate cancer, having the formula wherein: X is a moiety selected from the group of: n is selected from the integers 1 through 5; R1 is optionally substituted aryl or mono or bicyclic heteroaryl, with a proviso that heteroaryl is not thiadiazole; R2 is H or alkyl; R3 is H, COR5, COOR5, and CONR5R6; R4 is H, alkyl, alkenyl, alkynyl, aryl, mono or bicyclic heteroaryl, aralkyl, and mono or bicyclic heteroaralkyl, wherein the aryl or heteroaryl groups are optionally substituted; R5 and R6 are H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl, and noradamantyl or R5 and R6 taken together may form a 5-7 membered azacyclic ring, optionally containing an additional heteroatom selected from O, S, or NR4; when R5 or R6 are chosen from cycloalkyl or cycloalkenyl, the cyclic group may optionally
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: April 23, 2002
    Assignee: American Home Products Corporation
    Inventors: Wayne E. Childers, Michael G. Kelly, Yvette L. Palmer, Edward J. Podlesny
  • Publication number: 20020035112
    Abstract: The present invention provides novel compounds of the general formula: 1
    Type: Application
    Filed: October 12, 2001
    Publication date: March 21, 2002
    Applicant: American Home Products Corporation
    Inventors: Michael G. Kelly, Young H. Kang
  • Patent number: 6355643
    Abstract: The present invention comprises unsubstituted and substituted piperazine-containing compounds having alkanoyl, alkylsulfonyl, alkylamido or alkoxycarbonyl substituents, and having the formula A, which inhibit prenyl-protein transferases. In particular, the invention relates to prenyl-protein transferase inhibitors which are efficacious in vivo as inhibitors of geranylgeranyl-protein transferase type I (GGTase-I) and that inhibit the cellular processing of both the H-Ras protein and the K4B-Ras protein. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: March 12, 2002
    Assignee: Merck & Co., Inc.
    Inventors: William C. Lumma, John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Christopher J. Dinsmore, Jeffrey M. Bergman
  • Patent number: 6344456
    Abstract: The invention concerns compounds of formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein. Said compounds are useful in therapy as antithrombotic agents.
    Type: Grant
    Filed: January 10, 2001
    Date of Patent: February 5, 2002
    Assignee: Laboratoire L. Lafon
    Inventors: Christophe Yue, Marguerite Henry, Thierry Giboulot, Brigitte Lesur
  • Publication number: 20020013317
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: July 2, 2001
    Publication date: January 31, 2002
    Applicant: Neurogen Corporation
    Inventors: William Greenlee, Ashit Gangly, Jan W.F. Wasley
  • Patent number: 6340682
    Abstract: The present invention provides diamide derivatives represented by the following general formula (1): wherein A is a phenyl group or the like, which may be substituted, B is —CH═CH—, —C═C—, —(CH═CH)2—, —C≡C—CH═CH—, —CH═CH—C≡C—, phenylene or the like, and W is or and medicines comprising such a compound. These compounds have an excellent inhibitory effect on the production of an IgE antibody and are hence useful as antiallergic agents and the like.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: January 22, 2002
    Assignee: Kowa Co., Ltd.
    Inventors: Hiroyuki Ishiwata, Mototsugu Kabeya, Hiromichi Shigyo, Masami Shiratsuchi, Yukio Hattori, Hiroshi Nakao, Takao Nagoya, Seiichi Sato, Soichi Oda, Makoto Suda, Manabu Shibasaki
  • Patent number: 6335343
    Abstract: The present invention comprises piperazine/piperazinone-containing compounds having multicyclic ring system substituents on one of the piperazine/piperazinone nitrogens, which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: January 1, 2002
    Assignee: Merck & Co., Inc.
    Inventors: William C. Lumma, Jr., Anthony M. Smith, John T. Sisko
  • Patent number: 6335337
    Abstract: Novel compounds which are inhibitors of the binding of fibrinogen to the Gp iib/iiia platelet receptors, and which can be used therapeutically as antithrombotic agents.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: January 1, 2002
    Assignee: Laboratoire L. Lafon
    Inventors: Christophe Yue, Marguerite Henry, Thierry Giboulot, Brigitte Lesur
  • Publication number: 20010046991
    Abstract: A compound of formula I, 1
    Type: Application
    Filed: February 28, 2001
    Publication date: November 29, 2001
    Inventors: Siegfried Wurster, Mia Engstrom, Juha-Matti Savola, Iisa Hoglund, Jukka Sallinen, Antti Haapalinna, Andrei Yurievitch Tauber, Anna-Marja Katariina Hoffren, Harri Elias Salo
  • Patent number: 6316450
    Abstract: The invention relates to novel compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.
    Type: Grant
    Filed: January 10, 2000
    Date of Patent: November 13, 2001
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Steven Mark Bromidge, Stephen Frederick Moss
  • Patent number: 6313126
    Abstract: Compounds are provided which are useful for the treatment of serotonin-affected neurological disorders which comprise Wherein: R1, R2 and R3 are each, independently, hydrogen, halogen, CF3, alkyl, alkoxy, MeSO2, or together can form a 5-7 membered carbocyclic or heterocyclic ring; R4 is hydrogen, halogen, or alkyl; R5 is hydrogen, alkyl, alkylaryl, or aryl; R6 is hydrogen, halogen, CF3, CN, carbamide, or alkoxy; X1, X2 and X3 are each carbon or one of X1, X2 or X3 may be nitrogen; Y is carbon or nitrogen; and Z is carbon or nitrogen; or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: November 6, 2001
    Assignee: American Home Products Corp
    Inventors: Richard E. Mewshaw, Ping Zhou, Dahui Zhou, Kristin L. Meagher, Magda Asselin, Deborah A. Evrard, Adam M. Gilbert
  • Patent number: 6310066
    Abstract: The present invention provides novel compounds of the general formula: wherein R1 and R2 are H, OH, F, Cl, Br, I, 1 to 6 carbon alkyl or alkenyl, 1 to 6 carbon alkoxy, aryl, OR5, nitro, amino, CF3 or R1 and R2 are taken together to form a fused ring at the 2,3- or 3,4-positions providing a fused phenyl group or a benzodioxane group, or a 4- or 7-substituted indole group, or a 4- or 5- or 8-substituted quinoline group; R3 represents a group selected from hydrogen, a 1 to 6 carbon alkyl, a 1 to 4 carbon alkoxy or a halogen; R4 represents a group selected from hydrogen, 1 to 6 carbon alkyl or R5; R5 is CH2Ph in which the phenyl ring can be optionally substituted by a group selected from OMe, halogen, CF3; X is selected from a group represented by N, CR4, CHR4 and CHCH; A is selected from a group represented by N, NH, CH and CH2; B is selected from a group represented by ═O, ═S, H and H2; or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and m
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: October 30, 2001
    Assignee: American Home Products Corp.
    Inventors: Michael G. Kelly, Young H. Kang
  • Patent number: 6306859
    Abstract: Compounds of the Formula (I) wherein R2, Y, X and n are as defined in the specification which compounds are useful in the treatment of disorders associated with serotonergic neuron-related diseases.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: October 23, 2001
    Assignee: American Home Products Corporation
    Inventors: Wayne E. Childers, Michael G. Kelly, Gan Zhang, Yvette L. Palmer, Edward J. Podlesny
  • Patent number: 6281216
    Abstract: The present invention relates to a group of novel 2-aminoquinoline derivatives which are potent and selective agonists of the dopamine D4-receptor.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: August 28, 2001
    Assignee: Duphar International Research B.V.
    Inventors: Jacobus A. J. Den Hartog, Gerben M. Visser, Bartholomeus J. Van Steen, Martinus T. M. Tulp, Eric Ronken, Cornelis G. Kruse
  • Patent number: 6281215
    Abstract: New 4-(1-piperazinyl)benzoic acid derivatives of the formula (I) are described. Also described is methods for making these compounds and their use as therapeutic agents. In particular, the compounds find use in the treatment of diabetes.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: August 28, 2001
    Assignee: Merck Patent GmbH
    Inventors: Gérard Moinet, Gérard Botton, Liliane Doare, Micheline Kergoat, Didier Messangeau
  • Publication number: 20010003747
    Abstract: The invention relates to compound of formula (I): 1
    Type: Application
    Filed: December 5, 2000
    Publication date: June 14, 2001
    Inventors: Marie-Claude Viaud, G?eacute;rald Guillaumet, Philippe Daubos, Caroline Bennejean, Philippe Delagrange, Pierre Renard
  • Patent number: 6232314
    Abstract: Arylalkylpiperazine compounds (1) wherein B is aryl or optionally substituted aryl; R1 is hydroxy; R2 and R3 are the same or different and are independently selected from hydrogen or C1-3 alkyl; m is 0, 1 or 2; D is a linking chain of atoms which may be optionally substituted and which contains from 1 to 8 atoms in the chain; E is a phenolic antioxidant group or a corresponding amino derivative thereof wherein the phenolic hydroxyl is replaced by amino, are disclosed. The compounds have both free radical scavenging activity and block excitatory amino acid activity. Some compounds of the present invention also display an affinity for voltage-sensitive sodium channels.
    Type: Grant
    Filed: March 18, 1999
    Date of Patent: May 15, 2001
    Assignee: Monash University
    Inventors: Bevyn Jarrott, Philip Mark Beart, William Roy Jackson, Vijaya Bhaskar Kenche, Alan Duncan Robertson, Maree Patricia Collis
  • Patent number: 6225312
    Abstract: The invention relates to a group of new piperazine and piperidine compounds having interesting pharmacological properties. It has been found that compounds of formula (a) wherein A represents a heterocyclic group of 5-7 ring atoms wherein 1-3 heteroatoms from the group O, N and S are present; R1 is hydrogen or fluoro; R2 is C1-4-alkyl, C1-4-alkoxy or an oxo group, and p is 0, 1 or 2; Z represents carbon or nitrogen, and the dotted line is a single bond when Z is nitrogen, and a single or double bond when Z is carbon; R3 and R4 independently are hydrogen or C1-4-alkyl; n has the value 1 or 2; R5 is halogen, hydroxy, C1-4-alkoxy or C1-4-alkyl, and q is 0, 1, 2 or 3; Y is phenyl, furanyl or thienyl, which groups may be substituted with 1-3 substituents of the group hydroxy, halogen, C1-4-alkoxy, C1-4-alkyl, cyano, aminocarbonyl, mono- or di-C1-4-alkylaminocarbonyl; and salts thereof show high affinity for both the dopamine D2 and serotonin 5-HT1A receptors.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: May 1, 2001
    Assignee: Duphar International Research B.V.
    Inventors: Roelof Willem Feenstra, Cornelis Gerrit Kruse, Martinus Theodorus Maria Tulp, Wilma Kuipers, Stephen Kenneth Long
  • Patent number: 6221869
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof, wherein: R1, R2, R3, R4 are the same or different and represent hydrogen, C1-C6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-C6 alkoxy, —O2CR′, —NHCOR′, —COR′, —SOmR′, where R′ is C1-C6 alkyl and wherein m is 0, 1 or 2; or R1, R2, R3, R4 independently represent —CONR′R″, or —NR′R″ where R′ and R″ independently represent hydrogen or C1-C6 alkyl; R5 is hydrogen or C1-C6 alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: April 24, 2001
    Assignee: Neurogen Corporation
    Inventors: Jun Yuan, Xi Chen
  • Patent number: 6214829
    Abstract: Novel piperazine and piperidine derivative compounds having interesting and advantageous pharmacological properties. The disdosed compounds have the general formula (a) and salts thereof. These compounds have high affinity for both the dopamine D2 receptors and serotonine 5-HT1A receptors, rendering them useful for the treatment of CNS-disorders, in particular schizophrenia.
    Type: Grant
    Filed: August 31, 1998
    Date of Patent: April 10, 2001
    Assignee: Duphar International Research B.V.
    Inventors: Roelof W. Feenstra, Gerben M. Visser, Cornelis G. Kruse, Martinus T. M. Tulp, Stephen K. Long
  • Patent number: 6211181
    Abstract: This invention relates to compounds of the formula where X is halogen, R1 is H or a C1-C3 alkyl, R2 is H or OH and R3 is one of in which A is a single bond or a —CO(CH2)p—NH— group, R4 is H or —C(═NR5)NHR′5, R5 and R′5 are each H or a C1-C6 alkyl group, R6 is H or a C1-C3 alkyl group, m is 0, 1 or 2; n is 2, 3 or 4; p is 1, 2 or 3; plus their acid addition salts. The invention likewise relates to the method for their preparation and their therapeutic applications.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: April 3, 2001
    Assignee: Fournier Industrie et Sante
    Inventors: Pierre Dodey, Michel Bondoux, Patrick Houziaux, Martine Barth, Khan Ou